Intermittent Reduced Calorie Diet (IRCD) for Crohn's Disease
Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Crohn's Disease+2 MoreIntermittent Reduced Calorie Diet (IRCD) - Other
You have a chance of qualifying for this trial. We made sure your application will take less than 5 minutes.
Eligibility
18 - 70
All Sexes
What conditions do you have?
Select
Eligibility
18 - 70
All Sexes
What conditions do you have?
Select
Study Summary
This trial is investigating whether an Intermittent Calorie Reduced Diet that mimics fasting could help treat Crohn's disease by reducing inflammation.
0 Primary · 7 Secondary · Reporting Duration: At baseline versus within 6 days after 3rd cycle of IRCD and 3 months after 3rd cycle. 1 cycle of IRCD lasts 5 days and is administered once a month, followed by regular diet for the rest of the month.
Month 3
Effect of IRCD on patient quality of life: Short Inflammatory Bowel Disease questionnaire (SIBDQ)
Month 3
Number of Participants with Clinical remission as per CDAI
Number of Participants with Clinical response as per CDAI (100 points)
Number of Participants with Clinical response as per CDAI (70 points)
Day 6
Effect of IRCD on endoscopic outcomes
Number of Participants with Clinical remission as per Patient Reported Outcome (PRO) score
Patient global assessment
Day 6
Changes in clinical markers of disease activity
Month 3
Changes in gut metabolites (including short-chain fatty acid and bile acid profiles) and microbiome profiles (using 16S rRNA/shotgun metagenomics)
Day 6
Changes in cytokines/chemokines and immune cell profiles
Day 6
Change in C-reactive protein (CRP) at baseline versus after 3rd cycle of IRCD (or control at corresponding time point) in both IRCD and control group.
Change in Erythrocyte Sedimentation Rate (ESR) at baseline versus after 3rd cycle of IRCD (or control at corresponding time point) in both IRCD and control group.
Change in fecal calprotectin at baseline versus after 3rd cycle of IRCD (or control at corresponding time point) in both IRCD and control group.
Primary Treatment: Intermittent Reduced Calorie Diet (IRCD) · No Placebo Group · N/A
Intervention Arm
Other
Experimental Group · 1 Intervention: Intermittent Reduced Calorie Diet (IRCD) · Intervention Types: Other
Control ArmNoIntervention Group · 1 Intervention: Control Arm · Intervention Types:
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: at baseline versus within 6 days after 3rd cycle of ircd and 3 months after 3rd cycle. 1 cycle of ircd lasts 5 days and is administered once a month, followed by regular diet for the rest of the month.
Who is running the clinical trial?
Stanford UniversityLead Sponsor
2,170 Previous Clinical Trials
35,768,208 Total Patients Enrolled
Sidhartha R Sinha, MDPrincipal InvestigatorStanford University
1 Previous Clinical Trials
75 Total Patients Enrolled
Eligibility Criteria
Age 18 - 70 · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: